Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CPB1 | P15086 | 1/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17250893 | 1.00 | FOLH1 (0.62) | FOLH1HTTTGM2MMP2MMP9 | |
| SCHEMBL13471242 | 1.00 | FOLH1 (0.62) | FOLH1HTTTGM2MMP2MMP9 | |
| SCHEMBL8437001 | 0.96 | HTT (0.63) | FOLH1HTTTGM2MMP2MMP9 | |
| SCHEMBL18020349 | 0.96 | HTT (0.63) | FOLH1HTTTGM2MMP2MMP9 | |
| SCHEMBL15697210 | 0.96 | HTT (0.63) | FOLH1HTTTGM2MMP2MMP9 | |
| SCHEMBL16575045 | 0.95 | CPB1 (0.58) | FOLH1HTTTGM2MMP2MMP9 | |
| SCHEMBL14806727 | 0.91 | HTT (0.60) | FOLH1HTTTGM2MMP2MMP9 | |
| SCHEMBL16269912 | 0.90 | SLC1A3 (0.62) | FOLH1HTTTGM2LMNASMN1; SMN2 | |
| SCHEMBL18085402 | 0.90 | SLC1A3 (0.62) | FOLH1HTTTGM2LMNASMN1; SMN2 | |
| SCHEMBL14194799 | 0.90 | HTT (0.59) | FOLH1HTTTGM2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-20230310435-A1 | HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | INNOVATION PHARMACEUTICALS INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666571-B2 | Host defense protein (HDP) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract | INNOVATION PHARMACEUTICALS INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-9988375-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-8828956-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-05-29 | — | — | US | disclosed |
| US-20130274502-A1 | Processes For Preparing A Polymeric Compound | POLYMEDIX, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450467-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130078671-A1 | INCORPORATION OF TWO DIFFERENT NONCANONICAL AMINO ACIDS INTO A SINGLE PROTEIN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-28 | — | — | US | disclosed |
| US-8354556-B2 | Processes for preparing a polymeric compound | POLYMEDIX, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110098498-A1 | Processes For Preparing A Polymeric Compound | POLYMEDIX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098498-A1 | Processes For Preparing A Polymeric Compound | F12, ALG1, ABCB11 | FOLH1 819/4885HTT 2013/4885TGM2 4227/4885 |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | VIP, QPCT, TPT1 | FOLH1 193/4885HTT 896/4885TGM2 1240/4885 |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | FOLH1 19/4885HTT 2824/4885TGM2 567/4885 |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | FOLH1 1753/4885HTT 4363/4885TGM2 2566/4885 |
| US-11666571-B2 | Host defense protein (HDP) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract | FABP2, HMGB1, MASP2 | FOLH1 1646/4885HTT 1086/4885TGM2 448/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | FOLH1 695/4885HTT 1580/4885TGM2 2525/4885 |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | NCL, PARN, COIL | FOLH1 3466/4885HTT 1367/4885TGM2 2657/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | FOLH1 19/4885HTT 2824/4885TGM2 567/4885 |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | HAVCR2, B3GAT3, CSGALNACT1 | FOLH1 253/4885HTT 2961/4885TGM2 2023/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | FOLH1 133/4885HTT 1250/4885TGM2 847/4885 |
| US-20130078671-A1 | INCORPORATION OF TWO DIFFERENT NONCANONICAL AMINO ACIDS INTO A SINGLE PROTEIN | AARS1, NSUN3, NPEPPS | FOLH1 794/4885HTT 1020/4885TGM2 901/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | FOLH1 2860/4885HTT 627/4885TGM2 3516/4885 |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | FOLH1 1753/4885HTT 4363/4885TGM2 2566/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | FOLH1 335/4885HTT 1975/4885TGM2 3235/4885 |
| US-20230310435-A1 | HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | FABP2, HMGB1, MASP2 | FOLH1 1646/4885HTT 1086/4885TGM2 448/4885 |
| US-20130274502-A1 | Processes For Preparing A Polymeric Compound | F12, ALG1, ABCB11 | FOLH1 819/4885HTT 2013/4885TGM2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.